The world-class health research carried out at University College London (UCL) has been awarded £145m new funding from the National Institute of Health Research (NIHR).
UCL is the research partner of the NIHR UCLH BRC (Biomedical Research Centre), awarded £90m, the NIHR Great Ormond Street Hospital (GOSH) BRC, awarded £35m, and the NIHR Moorfields BRC, awarded £20m.
University College London Research Funding
The funding, announced by the UK Government today, October 14, will be spread over five years from December 2022 to November 2027, and will directly benefit patients through the development of ground-breaking new treatments and new techniques to diagnose disease.
Professor David Lomas, UCL Vice-Provost (Health), said: ‘I am delighted that the NIHR has recognised the outstanding work being done by our Biomedical Research Centres.
‘These collaborations between UCL Health and our NHS partners bring together academics and clinicians in a way that helps us translate breakthroughs in the lab into innovative new treatments, diagnostics and technologies. The renewed funding is excellent news and will result in real benefits for patients.’
UCL Biomedical Research Awarded
In total 20 BRCs in England received awards totalling £790m, following an open and competitive process judged by international experts and members of the public.
For this BRC funding round, university and NHS partnerships were invited to apply for up to £100 million over the five-year period. The BRC at UCLH and UCL is one of only two BRCs to be awarded over £90 million.
UCLH Chief Executive David Probert said: ‘This funding award is fantastic news and I want to congratulate everyone at UCLH and UCL involved in this achievement. Our strong partnership with UCL in research is key to the care we are able to offer at UCLH.’
Professor Bryan Williams, UCL Chair of Medicine, BRC Director and UCLH Director of Research said: ‘This was a very competitive funding round and our success is testament to the strength of our partnership working and the world-class strength of our research across a number of areas.
‘We are very pleased to receive this funding and I want to acknowledge the outstanding colleagues who have made this possible. This funding which will enable us to continue to deliver ground-breaking research in a number of areas including cancer, neurological diseases, infection and cardiovascular diseases.
‘Ultimately this is about improving the outcomes for patients – locally, nationally and internationally – who will benefit from this funding, thanks to innovations in care made possible by the BRC, changing and saving lives.’